Advertisement


Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

First International Summit on Interventional Pharmacoeconomics

Advertisement

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.



Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David A. Hyman, MD, JD, on Inclusive Shared Savings

Issues in Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Advertisement